Advancing Precision Medicine in High-Risk Breast Cancer: BRCA Mutations, Triple-Negative, and HR+/HER2– Subtypes - Episode 2
Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data
Panelists discuss the factors influencing the choice between abemaciclib and ribociclib for adjuvant CDK4/6 inhibitor therapy, including patient characteristics and safety profiles, and explore strategies for toxicity management, maintaining dose intensity, and addressing adherence or toxicity challenges in real-world clinical practice.
Video content above is prompted by the following:
- What specific patient characteristics influence your choice between abemaciclib and ribociclib?
- In which scenarios would you preferentially choose abemaciclib over ribociclib? Ribociclib over abemaciclib?
- Could you discuss your approach to toxicity management with adjuvant CDK4/6 inhibitors?
- How do the different safety profiles of abemaciclib and ribociclib impact your patient selection? How do you weigh clinical considerations and comorbidities in your selection considerations?
- What strategies have you found most effective for maintaining dose intensity while managing adverse effects?
- How has real-world experience with adjuvant CDK4/6 inhibitors matched up with clinical trial data?
- What have been your key learnings about patient selection and management?
- How do you handle patients who struggle with adherence or toxicity in the first few months?
Related Content:
